// App-Quantinova.ai

8000 : Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation with K maintenance in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM).

Researchers

Presenter

  • Kwee Yong

Principal Investigators

  • William Wilson

  • Karthink Ramasamy

  • Matthew J. Streetly

  • Jonathan Sive

  • Ceri Bygrave

  • Michael A Chapman

  • Ruth De Tute

  • Selina J Chavda

  • Elizabeth Phillips

  • Maria Cuadrado

  • Gavin Pang

  • Richard Jenner

  • Tushhar Dadaga

  • Sumaiya Kamora

  • James D. Cavenagh

  • Laura Clifton-Hadley

  • Roger G. Owen

  • Rakesh Popat

Medical Centers

  • Kings College London, London, United Kingdom

  • Gastroenterology Department, Kings College Hospital, London, United Kingdom

  • Cancer Research UK and UCL Cancer Trials Centre, University College London, London, United Kingdom

  • Haematology Department, Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Dept. of Haematology, University Hospital of Wales, Cardiff, United Kingdom

  • Haematology Department, Cambridge Institute for Medical Research, Cambridge, United Kingdom

  • HMDS Laboratory,St James' Institute of Oncology,Leeds,United Kingdom

  • UCL Cancer Institute, University College London,, London, United Kingdom

  • Division of Cancer Sciences, Manchester Cancer Research Centre, University of Manchester, Manchester, United Kingdom

  • Gastroenterology Department, Kings College Hospital, London, United Kingdom

  • Haematology Department, St Bartholomew's Hospital, Bart’s Health NHS Trust, London, United Kingdom

  • NIHR Clinical Research Facility, University College London Hospitals, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • carfilzomib Intravenous

Outcome

  • N/A

Study Design

  • Randomized

  • Non Inferiority

Phase

  • III

Study Id's

  • NCT02315716

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved